SCHEMBL4739368

SCHEMBL4739368

CC(=O)OC1CCCC2CC[C@@H]3[C@H](CC[C@]4(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@H]34)[C@]21C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC25A P30304 5/20 0.57
POLA1 P09884 1/20 0.57
CYP2D6 P10635 1/20 0.55
CYP2C19 P33261 1/20 0.55
INPP5D Q92835 1/20 0.54
USP2 O75604 1/20 0.54
VDR P11473 1/20 0.54
AKR1B10 O60218 1/20 0.52
AKR1B1 P15121 1/20 0.52
EFNA1 P20827 1/20 0.52
EPHA2 P29317 1/20 0.52
PSEN1 P49768 1/20 0.52
PSEN2 P49810 1/20 0.52
GPBAR1 Q8TDU6 1/20 0.52
APH1B Q8WW43 1/20 0.52
NCSTN Q92542 1/20 0.52
APH1A Q96BI3 1/20 0.52
PSENEN Q9NZ42 1/20 0.52
MEN1 O00255 1/20 0.52
LMNA P02545 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4740626 1.00 CDC25A (0.57) CDC25APOLA1CYP2D6CYP2C19INPP5D
SCHEMBL27525051 0.93 CDC25A (0.59) CDC25APOLA1CYP2D6CYP2C19INPP5D
SCHEMBL27986180 0.92 CYP2D6 (0.56) CDC25APOLA1CYP2D6CYP2C19INPP5D
SCHEMBL19991441 0.91 CDC25A (0.54) CDC25APOLA1CYP2D6CYP2C19INPP5D
SCHEMBL4737385 0.91 CDC25A (0.55) CDC25APOLA1CYP2D6CYP2C19INPP5D
SCHEMBL4736046 0.91 CDC25A (0.55) CDC25APOLA1CYP2D6CYP2C19INPP5D
SCHEMBL28186318 0.90 CDC25A (0.53) CDC25APOLA1CYP2D6CYP2C19INPP5D
SCHEMBL4728278 0.90 CYP2D6 (0.55) CDC25APOLA1CYP2D6CYP2C19INPP5D
SCHEMBL4735035 0.89 CDC25A (0.54) CDC25APOLA1CYP2D6CYP2C19INPP5D
SCHEMBL4738058 0.89 CDC25A (0.54) CDC25APOLA1CYP2D6CYP2C19INPP5D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030157158-A1 Enhanced liposomal thioretinaco ozonide compositions and liposomal carrier MCCULLY KILMER S (US) 2003-08-21 US claimed
WO-2003057192-A1 ENHANCED LIPOSOMAL THIORETINACO OZONIDE COMPOSITIONS AND LIPOSOMAL CARRIER MCCULLY KILMER S (US) 2003-07-17 WO claimed
JP-2200608-A None JP disclosed
WO-2008131192-A2 CRYSTALLINE CHOLESTROL AND PREVENTION OF ATHEROSCLEROSIS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2008-10-30 WO disclosed
WO-2008077247-A1 COATINGS FOR IMPLANTABLE MEDICAL DEVICES COMPRISING CHOLESTEROL MIV THERAPEUTICS INC. (CA) 2008-07-03 WO disclosed
US-6696082-B2 COMPLEX COMPRISING N-HOMOCYSTEINE THIOLACTONYL RETINAMIDE, COBALAMIN, OZONE, OXYGEN, AND ADENOSINE TRIPHOSPHATE; ANTICARCINGENIC, ANTITUMOR, AND VIRICIDAL AGENTS; ATHEROSCLEROSIS PREVENTION; AGING RESISTANCE MCCULLY KILMER S (US) 2004-02-24 US disclosed
US-20030157158-A1 Enhanced liposomal thioretinaco ozonide compositions and liposomal carrier MCCULLY KILMER S (US) 2003-08-21 US disclosed
WO-2003057192-A1 ENHANCED LIPOSOMAL THIORETINACO OZONIDE COMPOSITIONS AND LIPOSOMAL CARRIER MCCULLY KILMER S (US) 2003-07-17 WO disclosed
US-6274118-B1 INJECTING PATIENT HAVING ENDOCRINE CANCER IN NON-PROSTATIC TISSUE WITH BIOLOGICAL BINDING UNITS WHICH BIND TO PROSTATE SPECIFIC ANTIGEN PRODUCED BY NON-PROSTATIC TISSUE NORDION INTERNATIONAL INC. (CA) 2001-08-14 US disclosed
WO-1995002424-A1 LOCALIZATION AND THERAPY OF NON-PROSTATIC ENDOCRINE CANCER WITH AGENTS DIRECTED AGAINST PROSTATE SPECIFIC ANTIGEN NORDION INTERNATIONAL INC. (CA) 1995-01-26 WO disclosed
JP-H02200608-A COSMETIC POLA CHEM IND INC 1990-08-08 JP disclosed
US-4252719-A REMOVAL OF A TERTIARY HYDROGEN FROM A 5-A-STEROID BY CHLORINATING THE STEROID BEING FIRST ESTERIFIED BY AN IODOARYL-CONTAINING ESTERIFICATION AGENT RESEARCH CORPORATION (US) 1981-02-24 US disclosed